OneThree Biotech Raises $2.5M in Seed Funding
Summary
The round was co-led by Primary Venture Partners and Meridian Street Capital. The company intends to use the funds to scale and build out the platform’s backend infrastructure and further validate the technology through partnerships with biotech and pharma. Founded by Neel S. Madhukar, Ph.D., Olivier Elemento, Ph.D., Coryandar Gilvary, Ph.D., and Bradlay Pryde, OneThree Biotech uses a biology-driven artificial intelligence (AI) platform to optimize pre-clinical drug discovery and development. The results of the trial highlighted how their technology can improve the outcome of patients diagnosed with rare brain cancer by identifying treatments that could improve average survival from ~3 months to over a year for some patients. Beyond Oncoceutics, past and current partners and collaborators for OTB’s technology include Weill Cornell Medicine, Cornell Tech, Nvidia, Fox Chase Cancer Center, Cleveland Clinic, The Rockefeller University, Stanford University, and the Icahn School of Medicine at Mount Sinai.
Funding
Review available funding amount, funding date, investors, and linked company information related to OneThree Biotech Raises $2.5M in Seed Funding in the interactive ISVWorld profile.